Noticias de Eulerpool Daiichi Sankyo Co

Daiichi Sankyo Co Noticias de Acciones

Daiichi Sankyo Co es observado por muchos periodistas e inversores en todo el mundo. Aquí recopilamos las noticias más recientes de Daiichi Sankyo Co.

• 4 de junio ·

  Yahoo
  Daiichi Sankyo struck gold with ‘ADC’ cancer drugs. Its new CEO has to figure out what’s next.
• 4 de junio ·

  Yahoo
  DSNKY vs. ZTS: Which Stock Is the Better Value Option?
• 2 de junio ·

  Yahoo
  ENHERTU® Plus Pertuzumab Reduced the Risk of Disease Progression or Death by 44% Versus THP as First-Line Therapy in Patients with HER2 Positive Metastatic Breast Cancer in DESTINY-Breast09 Phase 3 Trial
• 1 de junio ·

  Yahoo
  DATROWAY® Continues to Show Promising Tumor Responses as Part of Combination Regimens in Patients with Early and Advanced Non-Small Cell Lung Cancer
• 31 de mayo ·

  Yahoo
  ENHERTU® Reduced the Risk of Death by 30% Versus Ramucirumab Plus Paclitaxel as a Second-Line Therapy in Patients with HER2 Positive Unresectable or Metastatic Gastric Cancer in DESTINY-Gastric04 Phase 3 Trial
• 30 de mayo ·

  Yahoo
  Daiichi Sankyo and MSD withdraw US application for lung cancer BLA
• 29 de mayo ·

  Yahoo
  Patritumab Deruxtecan Biologics License Application for Patients with Previously Treated Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer Voluntarily Withdrawn
• 27 de mayo ·

  SeekingAlpha
  Merck Proves Why It's Still A Top Pharma Pick
• 22 de mayo ·

  Yahoo
  Daiichi Sankyo Continues to Transform Treatment Landscape for Patients with Cancer with Practice-Changing Data at ASCO
• 19 de mayo ·

  Yahoo
  IDeate-Esophageal01 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Certain Patients with Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma